Combination of IPI-504 and docetaxel (DTX) improves efficacy in NSCLC xenograft models.

NCR nu/nu homozygous male mice were subcutaneously implanted with (A) H1993, (B) A549, (C) H292 and (D) H522 cells and treated with DMSO vehicle (black circles), IPI-504 (green squares), DTX (blue diamonds), or the combination of IPI-504 and DTX (red triangles). IPI-504 was administered by IP injection at a dose of 50 mg/kg, twice a week for a total of 6 doses. DTX was administered at 5 mg/kg (H522) or 15 mg/kg (H1993, A549, H292) by IP injection, weekly for a total of 3 doses. Numbers on graphs represent average percent tumor growth inhibition relative to vehicle-treated arm. Where indicated, * denotes statistical significance (p<0.05) between combination treatment and DTX treatment arms measured at day 30 (H1993, H549, H522) using Student's T-test.